RxDoctor Payments Data

Eric Ewald, MD

Cardiovascular Disease · N Chelmsford, MANPI 1639126311

Payments from drug & device makers

$926in general payments, 2019–2025

Across 43 payments — averaging $21.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$400
  • AstraZeneca$131
  • Johnson & Johnson$88
  • Pfizer$56
  • Merck$49
  • Amgen$46
  • plus $157 from 8 others

What the payments were for

  • Food & beverage$926100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$926 in reported general payments places this provider in the 40th percentile of 750 cardiovascular disease providers in Massachusetts.

See all cardiovascular disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$253,500
Medicare patients
2,776
Services billed
4,776

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban281$368,295
XareltoRivaroxaban131$174,588
EntrestoSacubitril/Valsartan24$29,521
Repatha SureclickEvolocumab17$19,193
Praluent PenAlirocumab18$9,413
Metoprolol Succinate507$8,037
Atorvastatin Calcium307$4,173
Rosuvastatin Calcium171$3,598
Flecainide Acetate36$3,120
Warfarin Sodium108$1,832
ClopidogrelClopidogrel Bisulfate139$1,818
Amlodipine Besylate280$1,799
Digoxin60$1,584
Lisinopril216$1,557
Labetalol Hcl39$1,356

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$56$368,295281 claims
Johnson & JohnsonXarelto$88$174,588131 claims
NovartisEntresto$400$29,52124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 750 cardiovascular disease providers in Massachusetts.

Other cardiovascular disease in N Chelmsford

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →